Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience |
Lim, A Young
(Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Ji Hyeon (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Jung, Ki Sun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Gwag, Hye Bin (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Do Hee (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Seok Jin (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Ga Yeon (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Jung Sun (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Hee-Jin (Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Soo-Youn (Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Jung Eun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Jeon, Eun-Seok (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Kihyun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) |
1 | Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596. DOI |
2 | Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008;103:776-787. DOI |
3 | Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371. DOI |
4 | Petre S, Shah IA, Gilani N. Review article: gastrointestinal amyloidosis: clinical features, diagnosis and therapy. Aliment Pharmacol Ther 2008;27:1006-1016. DOI |
5 | Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19:167-170. DOI |
6 | Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013;98:141-146. DOI |
7 | Madsen LG, Gimsing P, Schiodt FV. Primary (AL) amyloidosis with gastrointestinal involvement. Scand J Gastroenterol 2009;44:708-711. |
8 | Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc 1990;36:10-14. DOI |
9 | Tada S. Diagnosis of gastrointestinal amyloidosis with special reference to the relationship with amyloid fibril protein. Fukuoka Igaku Zasshi 1991;82:624-647. |
10 | Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001;111:535-540. DOI |
11 | Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22. DOI |
12 | Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993;68:763-767. DOI |
13 | James DG, Zuckerman GR, Sayuk GS, Wang HL, Prakash C. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol 2007;5:582-588. DOI |
14 | Gould M, Zarrin-Khameh N, Sellin J. Small bowel amyloidosis. Curr Gastroenterol Rep 2013;15:350. DOI |
15 | Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995. DOI |
16 | Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013;88:416-425. DOI |
17 | Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-4324. DOI |
18 | Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909. DOI |
19 | Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328. DOI |
20 | Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997;27:315-319. DOI |
21 | Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006;17:3458-3471. DOI |
![]() |